| GUANGZHOU-WONDFO-BIOTECH-CO-LTD |
GUANGZHOU-WONDFO-BIOTECH-CO-LTD |
85%
|
(Cobas, TinaQuant 3™), Bio-Rad (Variant 2™, Variant 2 Turbo™, D 100™, BioPlex 2200) Tosoh (G8™ and G11™), Arkray 8180™, Siemens DCA™, Sebia (Capyllaris 2™ and Capyllaris 3™), Shanghai Kehua Bio-Engin… |
| JNJ |
Johnson & Johnson |
72%
|
ur own direct sales force in the U.S. Our sales team in the U.S. is responsible for marketing and selling the Trinity Biotech range of point-of-care, infectious diseases, haemoglobins, autoimmune and… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from TRIB graph: ur own direct sales force in the U.S. Our sales team in the U.S. is responsible for marketing and selling the Trinity … |
| ABBOTT-DIAGNOSTICS-ARKRAY-BECTON-DICKENSON-BIO-R |
ABBOTT-DIAGNOSTICS-ARKRAY-BECTON-DICKENSON-BIO-R |
62%
|
l our products through our own direct sales force in the United States Our sales team in the United States is responsible for marketing and selling the Trinity Biotech range of point-of-care, infecti… |
| ABT |
Abbott Laboratories |
62%
|
Reciprocal relationship from ABT graph: Reciprocal relationship from TRIB graph: Reciprocal relationship from ABT graph: Reciprocal relationship from TRIB graph: Reciprocal relationship from ABT grap… |
| BIOPOOL-US-INC |
BIOPOOL-US-INC |
62%
|
. The information contained on, or that can be accessed from, our website does not form part of this Annual Report. The SEC maintains an Internet site that contains reports, proxy and information sta… |
| CLARK-LABORATORIES-INC |
CLARK-LABORATORIES-INC |
62%
|
. The information contained on, or that can be accessed from, our website does not form part of this Annual Report. The SEC maintains an Internet site that contains reports, proxy and information sta… |
| DAYLI-TRINITY-HOLDINGS-LIMITED |
DAYLI-TRINITY-HOLDINGS-LIMITED |
62%
|
g cash requirements. Additional funding may not be available on acceptable terms, or at all. In addition, we may not be able to access a portion of our existing cash, cash equivalents and investments… |
| EPICAPTURE-LIMITED |
EPICAPTURE-LIMITED |
62%
|
l our products through our own direct sales force in the United States Our sales team in the United States is responsible for marketing and selling the Trinity Biotech range of point-of-care, infecti… |
| HIBERGENE-DIAGNOSTICS-LTD |
HIBERGENE-DIAGNOSTICS-LTD |
62%
|
Business & Legal Studies from University College Dublin. Gary Keating, Chief Technology Officer , joined us in October 2022 . Dr Keating graduated from the University of Ulster at Jordanstown with a … |
| IMMCO-DIAGNOSTICS-INC |
IMMCO-DIAGNOSTICS-INC |
62%
|
. Amortisation will commence when the technologies are brought into commercial use. 144 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31 , 2025 12 GOODWILL AND INTANGIBLE ASSETS (CONTINUED)… |
| KONAMITE-LIMITED |
KONAMITE-LIMITED |
62%
|
. The information contained on, or that can be accessed from, our website does not form part of this Annual Report. The SEC maintains an Internet site that contains reports, proxy and information sta… |
| LYNQ-LIMITED |
LYNQ-LIMITED |
62%
|
Business & Legal Studies from University College Dublin. Gary Keating, Chief Technology Officer , joined us in October 2022 . Dr Keating graduated from the University of Ulster at Jordanstown with a … |
| METABOLOMICS-DIAGNOSTICS-LTD |
METABOLOMICS-DIAGNOSTICS-LTD |
62%
|
l our products through our own direct sales force in the United States Our sales team in the United States is responsible for marketing and selling the Trinity Biotech range of point-of-care, infecti… |
| MICO-IVD-HOLDINGS-LLC |
MICO-IVD-HOLDINGS-LLC |
62%
|
g cash requirements. Additional funding may not be available on acceptable terms, or at all. In addition, we may not be able to access a portion of our existing cash, cash equivalents and investments… |
| NET-LIMITED |
NET-LIMITED |
62%
|
ingly be subject to patent infringement claims. It is possible that a third-party may claim infringement against us. For example, because patent applications can take many years to issue, there may b… |
| PERCEPTIVE-CREDIT-HOLDINGS |
PERCEPTIVE-CREDIT-HOLDINGS |
62%
|
g cash requirements. Additional funding may not be available on acceptable terms, or at all. In addition, we may not be able to access a portion of our existing cash, cash equivalents and investments… |
| TRINITY-BIOTECH-MANUFACTURING-LIMITED |
TRINITY-BIOTECH-MANUFACTURING-LIMITED |
62%
|
. The information contained on, or that can be accessed from, our website does not form part of this Annual Report. The SEC maintains an Internet site that contains reports, proxy and information sta… |
| WAVEFORM-TECHNOLOGIES-INC |
WAVEFORM-TECHNOLOGIES-INC |
62%
|
s through our clinical chemistry business. Infectious Diseases We manufacture kits for the detection of specialty and esoteric biomarkers of infectious diseases and other associated laboratory produc… |
